Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at CTAD 2025

TOKYO and CAMBRIDGE, Mass., Dec 4, 2025 - (JCN Newswire via SeaPRwire.com) -  Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest findings on time savings with continued treatment with humanized…

Oman’s 10-Year Golden Residency Program Attracts Global Investors Seeking Stability and Long-Term Access

Muscat, Oman, Dec 4, 2025 - (ACN Newswire via SeaPRwire.com) - Three months after its introduction, Oman's 10-Year Golden Residency is emerging as one of the region's most compelling long-term residency pathways, attracting rising interest from investors, entrepreneurs, and internationally mobile families seeking stability, transparent regulation, and strategic access to high-growth…